Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 772

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of RO7434656 for Patients with Primary IgA Nephropathy at High Risk of Progression

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Isis 696844

Study on GnRH Agonists for Ovulation and Luteal Support in IVF Patients: Comparing GnRH Agonist with hCG and Progesterone

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Nafarelin

Study on LSTA1 and Temozolomide for Patients with Newly Diagnosed Glioblastoma Multiforme

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Lsta1

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab

Study on Alteplase for Vision Recovery in Patients with Acute Central Retinal Artery Occlusion

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase

Cholangiocarcinoma

Not recruiting

Study of Futibatinib for Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Futibatinib

Study of Sacituzumab Govitecan for Patients with Advanced Esophagogastric Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan

Binge eating

Not recruiting

Study on BP1.4979 for Treating Binge Eating Disorder in Women with Moderate to Severe Symptoms

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:N-[4-[2-[4-(3-Cyanophenyl)Piperazin-1-Yl]Ethyl]Cyclohexyl]-3-Methoxypropanamide

Plasma cell myeloma

Not recruiting

Study on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib

Neoplasm malignant

Not recruiting

Study of HST-1011 Alone and with Cemiplimab for Patients with Advanced Solid Tumors Not Responding to Standard Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab

Cerebrovascular accident+1

Not recruiting

Study on the Effectiveness of Alteplase as an Add-On to Mechanical Thrombectomy for Patients with Acute Ischemic Stroke

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase

Study Comparing Ibrutinib and Venetoclax with Chlorambucil and Obinutuzumab for First-line Treatment in Patients with Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.